Research ArticleCLINICAL INVESTIGATIONS
68Ga-DOTA-Tyr3-Octreotide PET for Assessing Response to Somatostatin-Receptor–Mediated Radionuclide Therapy
Michael Gabriel, Andreas Oberauer, Georg Dobrozemsky, Clemens Decristoforo, Daniel Putzer, Dorota Kendler, Christian Uprimny, Peter Kovacs, Reto Bale and Irene J. Virgolini
Journal of Nuclear Medicine September 2009, 50 (9) 1427-1434; DOI: https://doi.org/10.2967/jnumed.108.053421
Michael Gabriel
Andreas Oberauer
Georg Dobrozemsky
Clemens Decristoforo
Daniel Putzer
Dorota Kendler
Christian Uprimny
Peter Kovacs
Reto Bale
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 50, Issue 9
September 2009
68Ga-DOTA-Tyr3-Octreotide PET for Assessing Response to Somatostatin-Receptor–Mediated Radionuclide Therapy
Michael Gabriel, Andreas Oberauer, Georg Dobrozemsky, Clemens Decristoforo, Daniel Putzer, Dorota Kendler, Christian Uprimny, Peter Kovacs, Reto Bale, Irene J. Virgolini
Journal of Nuclear Medicine Sep 2009, 50 (9) 1427-1434; DOI: 10.2967/jnumed.108.053421
68Ga-DOTA-Tyr3-Octreotide PET for Assessing Response to Somatostatin-Receptor–Mediated Radionuclide Therapy
Michael Gabriel, Andreas Oberauer, Georg Dobrozemsky, Clemens Decristoforo, Daniel Putzer, Dorota Kendler, Christian Uprimny, Peter Kovacs, Reto Bale, Irene J. Virgolini
Journal of Nuclear Medicine Sep 2009, 50 (9) 1427-1434; DOI: 10.2967/jnumed.108.053421
Jump to section
Related Articles
Cited By...
- Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
- Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects
- Inflammation-Based Index and 68Ga-DOTATOC PET-Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with 90Y-DOTATOC
- Tumor-to-Blood Ratio for Assessment of Somatostatin Receptor Density in Neuroendocrine Tumors Using 68Ga-DOTATOC and 68Ga-DOTATATE
- A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on 68Ga-DOTATATE Uptake in Patients with Neuroendocrine Tumors
- Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy
- SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework
- Parametric Net Influx Rate Images of 68Ga-DOTATOC and 68Ga-DOTATATE: Quantitative Accuracy and Improved Image Contrast
- Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions
- A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management
- Appendiceal neuroendocrine neoplasms: diagnosis and management
- Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art
- Quantitative and Qualitative Intrapatient Comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: Net Uptake Rate for Accurate Quantification
- The use of biomarkers in neuroendocrine tumours
- Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors
- PET of Somatostatin Receptor-Positive Tumors Using 64Cu- and 68Ga-Somatostatin Antagonists: The Chelate Makes the Difference
- Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin
- Incidence of Increased 68Ga-DOTANOC Uptake in the Pancreatic Head in a Large Series of Extrapancreatic NET Patients Studied with Sequential PET/CT
- Imaging Expression of the Human Somatostatin Receptor Subtype-2 Reporter Gene with 68Ga-DOTATOC
- Phase I Trial of 90Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors
- 68Ga-DOTATATE PET/CT for the Early Prediction of Response to Somatostatin Receptor-Mediated Radionuclide Therapy in Patients with Well-Differentiated Neuroendocrine Tumors